Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...

Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat ...

Q1 2025 Management View CEO Steve MacMillan announced Q1 2025 revenue of $1.022 billion, reflecting a 1% increase on a constant currency basis, aligned with the company’s guidance. Non-GAAP EPS ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Hologic (HOLX – Research Report) yesterday. The company’s shares closed yesterday at ...

Hologic Inc (NASDAQ:HOLX). reported its financial results for the first quarter of fiscal year 2025, showing a slight beat in earnings per share (EPS) but falling short on revenue expectations. The ...

Lowers FY25 revenue view to $4.05B-$4.1B from $4.15B-$4.2B, consensus $4.15B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Hologic (HOLX) delivered earnings and revenue surprises of 0.98% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

The stock's rise snapped a three-day losing streak.

MARLBOROUGH, Mass. (AP) — MARLBOROUGH, Mass. (AP) — Hologic Inc. (HOLX) on Wednesday reported fiscal first-quarter profit of $201 million. On a per-share basis, the Marlborough, Massachusetts-based ...

Hologic (NASDAQ:HOLX – Get Free Report) will likely be issuing its quarterly earnings data after the market closes on ...